Derek Manas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Derek Manas has a total of 530 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah Khalid Malik
Department of Hepatobiliary and Transplant Surgery, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
8 shared publications - Mark Hudson
Language and the Anthropocene Research Group, Max Planck Institute of Geoanthropology
4 shared publications - Stuart Robinson
Department of HPB Surgery, Freeman Hospital, Newcastle Upon Tyne, UK
4 shared publications - Brian Davidson
University College London 7 Division of Surgery & Interventional Sciences London
3 shared publications - Helen Louise Reeves
The Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK
3 shared publications - Steven Masson
The Newcastle upon Tyne Hospitals NHS Foundation Trust , Freeman Hospital, Freeman Road, High Neaton, Newcastle upon Tyne, NE7 7DN
3 shared publications
Latest Publications
- 13 November 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Primary Tumor Biology, Recurrence and Survival After Colorectal Liver Metastasis Resection: The BIO-CRLM Study
Objective: To evaluate whether integrated primary tumor biology, combining primary tumor location and RAS/BRAF status, defines recurrence phenotypes and survival trajectories after liver resection for colorectal liver metastases (CRLM). Summary Background Data: Selection for resection remains largely morphology-based, although tumor biology strongly influences post-hepatectomy outcomes. Primary tumor site and RAS/BRAF status are individually prognostic, but whether their integration identifies distinct post-resection trajectories is unclear. Methods: An international multicenter cohort of patients undergoing liver resection for CRLM between 2017 and 2023 was analyzed. Integrated biology was defined a priori as left-sided-wild-type, right-sided-wild-type, rectal-wild-type, left-sided-RAS-mutant, right-sided-RAS-mutant, rectal RAS-mutant, and BRAF-mutant disease. Primary outcomes were recurrence-free survival (RFS) and overall survival (OS). Secondary outcomes included early recurrence, disseminated first recurrence, and first recurrence phenotype. Results: Among 3162 patients from 44 centers, 2415 (76.4%) developed recurrence and 1342 (42.4%) died. Integrated biology was independently associated with both RFS and OS (global P P P P P <0.001) relative to liver-only recurrence. Conclusions: Integrated primary tumor biology identifies clinically distinct post-hepatectomy disease trajectories after CRLM resection. Combining primary tumor site with RAS/BRAF status may support preoperative counseling, surveillance planning, and trial stratification.
- 13 November 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Primary Tumor Biology, Recurrence and Survival After Colorectal Liver Metastasis Resection: The BIO-CRLM Study
Objective: To evaluate whether integrated primary tumor biology, combining primary tumor location and RAS/BRAF status, defines recurrence phenotypes and survival trajectories after liver resection for colorectal liver metastases (CRLM). Summary Background Data: Selection for resection remains largely morphology-based, although tumor biology strongly influences post-hepatectomy outcomes. Primary tumor site and RAS/BRAF status are individually prognostic, but whether their integration identifies distinct post-resection trajectories is unclear. Methods: An international multicenter cohort of patients undergoing liver resection for CRLM between 2017 and 2023 was analyzed. Integrated biology was defined a priori as left-sided-wild-type, right-sided-wild-type, rectal-wild-type, left-sided-RAS-mutant, right-sided-RAS-mutant, rectal RAS-mutant, and BRAF-mutant disease. Primary outcomes were recurrence-free survival (RFS) and overall survival (OS). Secondary outcomes included early recurrence, disseminated first recurrence, and first recurrence phenotype. Results: Among 3162 patients from 44 centers, 2415 (76.4%) developed recurrence and 1342 (42.4%) died. Integrated biology was independently associated with both RFS and OS (global P P P P P <0.001) relative to liver-only recurrence. Conclusions: Integrated primary tumor biology identifies clinically distinct post-hepatectomy disease trajectories after CRLM resection. Combining primary tumor site with RAS/BRAF status may support preoperative counseling, surveillance planning, and trial stratification.
- Open Access
- 20 July 2026
- Published by Elsevier in American Journal of Transplantation
Waitlist suspension is associated with persistent reduction in access to liver transplantation
- 20 July 2026
- Published by Elsevier in American Journal of Transplantation
Open AccessWaitlist suspension is associated with persistent reduction in access to liver transplantation
- 3 April 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (8) , 1307-1318
The United Kingdom’s experience of controlled donation after circulatory death direct procurement of lungs with concomitant abdominal normothermic regional perfusion with an analysis of short-term outcomes
- 3 April 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (8) , 1307-1318
The United Kingdom’s experience of controlled donation after circulatory death direct procurement of lungs with concomitant abdominal normothermic regional perfusion with an analysis of short-term outcomes
- Open Access
- 25 July 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (2) , 459-468
Severe Cholestasis Predicts Recurrent Primary Sclerosing Cholangitis Following Liver Transplantation
INTRODUCTION: Primary sclerosing cholangitis (PSC) may reoccur following liver transplantation (LT), and the diagnosis established once imaging studies demonstrate the diagnostic cholangiographic appearance. To evaluate whether the development of recurrent PSC (rPSC) is associated with cholestasis soon after LT, we studied whether changes in hepatic biochemistry within the first 12 months were linked with the development of rPSC and graft loss. METHODS: We conducted a retrospective cohort analysis of 158 transplant recipients with PSC in Canada and 549 PSC transplant recipients from the United Kingdom. We evaluated serum liver tests within 12 months after LT and the subsequent development of a cholangiographic diagnosis of rPSC as a time-dependent covariate using Cox regression. Severe cholestasis was defined as either alkaline phosphatase > 3× upper limit of normal or total bilirubin > 100 μmol/L. RESULTS: Patients who developed rPSC were more likely to have severe cholestasis vs those without at 3 months (20.5% vs 8.2%, P = 0.011), at 6 months (17.9% vs 10.0%, P = 0.026), and 12 months (15.4% vs 7.8%, P = 0.051) in the Canadian cohort and at 12 months in the UK cohort (27.9% vs 12.6%, P < 0.0001). By multivariable analysis, development of severe cholestasis in the Canadian cohort at 3 months (hazard ratio [HR] = 2.41, P = 0.046) and in the UK cohort at 12 months (HR = 3.141, P < 0.0001) was both associated with rPSC. Severe cholestasis at 3 months in the Canadian cohort was predictive of graft loss (HR = 3.88, P = 0.0001). DISCUSSION: The development of cholestasis within 3–12 months following LT was predictive of rPSC and graft loss.
- 25 July 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (2) , 459-468
Open AccessSevere Cholestasis Predicts Recurrent Primary Sclerosing Cholangitis Following Liver Transplantation
INTRODUCTION: Primary sclerosing cholangitis (PSC) may reoccur following liver transplantation (LT), and the diagnosis established once imaging studies demonstrate the diagnostic cholangiographic appearance. To evaluate whether the development of recurrent PSC (rPSC) is associated with cholestasis soon after LT, we studied whether changes in hepatic biochemistry within the first 12 months were linked with the development of rPSC and graft loss. METHODS: We conducted a retrospective cohort analysis of 158 transplant recipients with PSC in Canada and 549 PSC transplant recipients from the United Kingdom. We evaluated serum liver tests within 12 months after LT and the subsequent development of a cholangiographic diagnosis of rPSC as a time-dependent covariate using Cox regression. Severe cholestasis was defined as either alkaline phosphatase > 3× upper limit of normal or total bilirubin > 100 μmol/L. RESULTS: Patients who developed rPSC were more likely to have severe cholestasis vs those without at 3 months (20.5% vs 8.2%, P = 0.011), at 6 months (17.9% vs 10.0%, P = 0.026), and 12 months (15.4% vs 7.8%, P = 0.051) in the Canadian cohort and at 12 months in the UK cohort (27.9% vs 12.6%, P < 0.0001). By multivariable analysis, development of severe cholestasis in the Canadian cohort at 3 months (hazard ratio [HR] = 2.41, P = 0.046) and in the UK cohort at 12 months (HR = 3.141, P < 0.0001) was both associated with rPSC. Severe cholestasis at 3 months in the Canadian cohort was predictive of graft loss (HR = 3.88, P = 0.0001). DISCUSSION: The development of cholestasis within 3–12 months following LT was predictive of rPSC and graft loss.
- 7 March 2024
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (2) , 108248
Surgical management, including the role of transplantation, for intrahepatic and peri-hilar cholangiocarcinoma
- 7 March 2024
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (2) , 108248
Surgical management, including the role of transplantation, for intrahepatic and peri-hilar cholangiocarcinoma
- Open Access
- 14 February 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (7) , 1247-1256
The impact of time to death in donors after circulatory death on recipient outcome in simultaneous pancreas-kidney transplantation
- 14 February 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (7) , 1247-1256
Open AccessThe impact of time to death in donors after circulatory death on recipient outcome in simultaneous pancreas-kidney transplantation
- 22 September 2023
- Published by Springer Nature
- p. 1267-1273
The Impact of the COVID-19 Pandemic on Pancreas Transplantation
- 22 September 2023
- Published by Springer Nature
- p. 1267-1273
The Impact of the COVID-19 Pandemic on Pancreas Transplantation
- Open Access
- 2 September 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (1) , 104-114
International consensus recommendations on face transplantation: A 2-step Delphi study
- 2 September 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (1) , 104-114
Open AccessInternational consensus recommendations on face transplantation: A 2-step Delphi study
- Open Access
- 5 April 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (7) , 873-874
The future of organ donation in Europe: Is there a role for organ recovery centers?
- 5 April 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (7) , 873-874
Open AccessThe future of organ donation in Europe: Is there a role for organ recovery centers?